The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
09-Aug-16
$NA
Target:
Bionomics Limited
Advised ASX-listed Bionomics, a clinical stage biopharmaceutical company focused on the treatment of serious central nervous system disorders and cancer, on a consultation process with shareholders following calls for Board change, leading to the formation of a shareholder working group of leading institutional investors and company-led Board renewal.
28-Jun-16
$NA
Target:
US rights to an authorized generic version of Adderall XR
Acquiror:
Prasco Laboratories
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to an authorized generic version of Adderall XR
28-Jun-16
$652 million
Target:
US rights to 37 approved and 5 pipeline generic products
Acquiror:
Mayne Pharma Group Limited
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 42 generic products
21-Jun-16
$586 million
Target:
US rights to a broad portfolio of 18 generic products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Impax Laboratories, Inc.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to a broad portfolio of 18 generic products to Impax Laboratories, Inc.
20-Jun-16
$NA
Target:
US rights to 2 generic drug products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Zydus Cadila
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 2 generic drug products to Zydus Cadila
16-Jun-16
$40 million
Target:
US rights to 5 generic injectable drug products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Sagent Pharmaceuticals, Inc.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 5 generic injectable drug products to Sagent Pharmaceuticals, Inc.
11-Jun-16
$350 million
Target:
US rights to 8 generic drug products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Dr. Reddy’s Laboratories
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 8 generic drug products to Dr. Reddy’s Laboratories
01-Jun-16
$221 million
Target:
Patties Foods Ltd
Acquiror:
Pacific Equity Partners
Advised Patties Foods Ltd (ASX:PFL), the leading Australian branded frozen food Company, with market leadership in the frozen savoury and frozen dessert segments, on its proposed sale to Pacific Equity Partners via Scheme of Arrangement
27-Jul-15
$40.5 billion
Target:
Allergan Generics
Acquiror:
Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company, on the acquisition of Allergan plc’s Generics business
21-Apr-15
$963 million
Target:
Refinancing of syndicated bank debt facilities
Acquiror:
Primary Health Care
Advised Primary Health Care on the refinancing of its A$1.25 billion syndicated bank debt facilities
06-Mar-15
$NA
Target:
Kerry Pinnacle
Acquiror:
Pacific Equity Partners
Advised Kerry Group plc, a global leader in food ingredients and flavor technologies, on the sale of its Australian subsidiary Kerry Pinnacle, an integrated manufacturer and distributor of bakery ingredients and prepared bakery products, to Pacific Equity Partners
03-Mar-15
$66 million
Target:
The Warehouse Group Limited
Advised Woolworths Limited, Australia’s largest supermarket operator, on strategic options for the divestment of its 8.8% holding in The Warehouse Group, New Zealand’s largest general merchandise retailer
02-Mar-15
$107 million
Target:
Lion's Everyday Cheese Business
Acquiror:
Warrnambool Cheese & Butter
Advised Lion, a leading Australasian food and beverage company wholly owned by Japanese conglomerate Kirin, on the sale of its Everyday Cheese business to Warrnambool Cheese & Butter, a listed Australian dairy company controlled by the Canadian dairy player Saputo
01-Oct-14
$NA
Target:
Modern Star Pty Ltd
Acquiror:
Navis Capital
Advised Modern Star, Australia and New Zealand’s #1 supplier of education resources and educational toys, on the sale of 90% of its shares to Navis Capital, a leading private equity group focused on investments in South and Southeast Asia
28-Jul-14
$90 million
Target:
Clinuvel Pharmaceuticals Limited
Acquiror:
Retrophin, Inc.
Advised Clinuvel, a biopharmaceutical company focused on developing drugs for the treatment of a range of severe skin disorders, in response to an unsolicited proposal to acquire the business from Retrophin, a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases
25-Jul-14
$NA
Target:
Stakes in David Jones and Country Road
Acquiror:
Woolworths Holdings
Advised Solomon Lew in reviewing his strategic options in relation to David Jones and Country Road. Mr Lew ultimately sold his 11.8% stake in the tightly held Country Road to Woolworths Holdings. Woolworths Holdings also acquired David Jones, Australia’s premier department store, in which Mr Lew held a 9.9% stake
20-Feb-13
$120 million
Target:
Trivett Automotive Group
Acquiror:
Inchcape plc
Advised Inchcape plc, the leading independent international automotive distributor and retailer, on the acquisition of Trivett Automotive Group, the leading luxury and premium automotive group in Australia
07-Dec-12
$43 million
Target:
Champion Flour Limited
Acquiror:
Nisshin Seifun Group Inc.
Advised Goodman Fielder, a leading Australian listed food company, on the sale of its New Zealand flour milling business, Champion Flour, to Nisshin Seifun Group Inc.
26-Sep-12
$NA
Target:
Dick Smith Electronics, a subsidiary of Woolworths Limited
Acquiror:
Anchorage Capital Partners
Advised Woolworths Limited, Australia’s largest supermarket operator, on the sale of its Consumer Electronics retail chain, Dick Smith Electronics, to Anchorage Capital Partners
18-Jun-12
$386 million
Target:
Little World Beverages
Acquiror:
Lion / Kirin
Advised Lion on the acquisition of Little World Beverages, Australia’s largest listed brewer and one of the country’s leading players in the Craft beer segment
21-Nov-11
$689 million
Target:
iNova Pharmaceuticals
Acquiror:
Valeant Pharmaceuticals
Advised Archer Capital and Ironbridge Capital on the sale of iNova Pharmaceuticals, a leading pharmaceuticals company that sells and distributes a range of prescription and over-the-counter products in Australia, New Zealand, Asia and Southern Africa, to Valeant Pharmaceuticals
17-Oct-11
$630 million
Target:
Rebel Group Limited
Acquiror:
Super Retail Group
Advised Super Retail Group on the acquisition of Rebel Group Limited, Australia’s largest retailer of sporting goods, for A$610 million and the associated A$334 million capital raising used to fund the acquisition
27-Sep-11
$259 million
Target:
Goodman Fielder Limited
Advised Goodman Fielder Limited, an Australian consumer foods manufacturer and distributor, on its equity capital raising via a rights issue
13-May-11
$NA
Target:
Bionomics Ltd
Advised Bionomics Ltd, in relation to the tender process run by Bionomics’ largest shareholder, Start-up Australia Ventures (“Start-up”), for its 28% stake in the company, follow on sell-down of Start-up’s stake to 8% and associated capital raising by Bionomics
13-Apr-11
$NA
Target:
Retail Apparel Group
Acquiror:
Navis Capital
Advised CHAMP Ventures on the sale of its portfolio company Retail Apparel Group, an Australian based men’s specialty apparel retailer, to Navis Capital, one of the largest regional private equity business in south-east Asia